Carotuximab Drug Asset Due Diligence Report 2026

This Carotuximab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Carotuximab can convert its Monoclonal antibody profile and ENG biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Carotuximab (query alias: Carotuximab)
Modality / target	Monoclonal antibody; ENG; ENG inhibitors, Angiogenesis inhibitors
Highest global status	Phase 2
Originator	Roswell Park Comprehensive Cancer Center, TRACON Pharmaceuticals, Inc.
Active developers	Cedars-Sinai Medical Center, Kairos Pharma Ltd.

The MCP disease footprint includes Metastatic castration-resistant prostate cancer, Non-Small Cell Lung Cancer, EGFR-mutated non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05534646	Phase 2	Recruiting	100	Primary endpoint not disclosed in English source
NCT05401110	Phase 1	Recruiting	60	Primary endpoint not disclosed in English source
NCT03780010	Phase 1	Completed	15	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

2433P - Preliminary safety and clinical activity from a phase II study of apalutamide + carotuximab in advanced, castration-resistant prostate cancer

Phase 2; n=10; evaluation: Positive. Reported fields: AE = Adverse events were consistent with previous studies of carotuximab and included grade 1-2 headache (88%), epistaxis (50%), fatigue (50%), and nausea (50%).

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Phase 2; n=10; evaluation: Positive. Reported fields: Safety = today announces positive safety results from its ongoing Phase 2 clinical trial.The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten enrolled patients.

A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2; n=15; evaluation: Not stated in English source. Reported fields: Number of Participants Who Experienced Dose-limiting Toxicities = 0 Pts ; Number of Participants Who Experienced Dose-limiting Toxicities = 1 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Carotuximab addresses Metastatic castration-resistant prostate cancer, Non-Small Cell Lung Cancer, EGFR-mutated non-small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-06-03	Kairos and Enviro entered into a share exchange whereby Kairos acquired of all of the common stock of Enviro in exchange for stock in Kairos.	Not disclosed	US$0.0M stated total
2021-05-21	Enviro entered into a License Agreement with Tracon Pharmaceutical, Inc.	Not disclosed	US$0.1M upfront; US$1.0M milestones
2017-12-21	TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China	Phase 3	US$3.0M upfront; US$140.5M milestones; US$143.5M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions and methods for use in KRAS-targeted therapies for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Methods for in VIVO targeted delivery of a payload”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising human hyaluronidase PH20 and drug”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO